NEODOLPASSE 0.30mg/0.12mg/ml 0.30mg+0.12mg / ml solution for infusion medication leaflet

M01AB55 diclofenac + orphenadrine citrate • Musculo-skeletal system | Antiinflammatory and antirheumatic products, non-steroids | Acetic acid derivatives and related substances

The combination of diclofenac and orphenadrine citrate is used for the treatment of pain and inflammation associated with musculoskeletal conditions. Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID), while orphenadrine has muscle relaxant properties.

The medication is administered orally or via injection, as directed by a doctor. It is important to follow the recommended dose to minimize the risk of side effects.

Side effects may include nausea, abdominal pain, dizziness, or drowsiness. In rare cases, severe allergic reactions, gastric ulcers, or renal failure may occur.

This combination is not recommended for patients with active gastric ulcers, severe renal impairment, or hypersensitivity to any of the components.

General data about NEODOLPASSE 0.30mg/0.12mg/ml 0.30mg+0.12mg / ml

Substance: diclofenac + orphenadrine citrate

Date of last drug list: 10-04-2026

Commercial code: W64231003

Concentration: 0.30mg+0.12mg / ml

Pharmaceutical form: solution for infusion

Quantity: 10

Product type: original

Price: 361.80 RON

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: FRESENIUS KABI AUSTRIA GMBH - AUSTRIA

Holder: FRESENIUS KABI ROMANIA S.R.L. - ROMANIA

Number: 6185/2014/03

Shelf life: 1 year

Other substances similar to diclofenac + orphenadrine citrate

Compensation lists for NEODOLPASSE 0.30mg/0.12mg/ml 0.30mg+0.12mg / ml FRESENIUS

C3 - Sublist C - section C3 (children, pregnant women and postpartum women) with 100% discount from the reference price

Price

Copayment

Patient

361.80 RON

361.80 RON

0.00 RON